Cell Therapy Market_医药健康与生命科学_环球市场_越省事-中企出海越南首选平台

Report Overview

The Global Cell Therapy Market size is expected to be worth around US$ 30.6 Billion by 2034, from US$ 6.4 Billion in 2024, growing at a CAGR of 16.7% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 53.1% share and holds US$ 3.3 Billion market value for the year.

Cell Therapy Market Size Analysis

The global cell therapy market is witnessing a remarkable growth phase, fueled by a surge in demand for regenerative medicine. Cell therapy makes use of health cells to treat various medical conditions. It typically involves transplanting healthy cells to repair damaged cells in the human body. Cell therapy can be used to treat various diseases and medical conditions including oncology, cardiovascular disease, musculoskeletal disorders, and skin treatment.

The concept dates back to the 19th century, but significant advances have been made in recent years, particularly with the advent of stem cell research and biotechnology. The cells used in these therapies can be from the patient (autologous cells) or from a donor (allogeneic cells). They can be derived from various sources, such as bone marrow, blood, or even embryonic tissue. Cell therapy aims to replace, repair, regenerate, or enhance the biological function of damaged tissues or organs.

The therapeutic approach encompasses a variety of treatments using either stem cells or other types of cells, which can be either single or multiple cell-based. These therapies may involve genetic modifications or specific formulations, and can be applied in various ways including topical applications, injections, infusions, or through the use of bioscaffolds and scaffold-free methods. Cell therapy is being explored across numerous medical fields, including regenerative medicine, immunotherapy, and cancer treatment. While many cell therapies are still in the initial phases of development (primarily phase 1/2 trials), there are notable exceptions. These include established treatments like bone marrow/stem cell transplants and hepatocyte transplantation, as well as FDA-approved therapies such as sipuleucel-T (PROVENGE), azficel-T (LAVIV), autologous cultured chondrocytes on porcine collagen (MACI), and tisagenlecleucel (KYMRIAH).

Cell Therapy Market, Global Analysis, 2020-2024 (US$ Billion)

Cell Therapy Market, Therapy Type Analysis, 2020-2024 (US$ Billion)

Cell Therapy Market, Region Analysis, 2020-2024 (US$ Billion)

Region	2020	2021	2022	2023	2024
North America	2.34	2.52	2.74	3.00	3.39
Europe	0.85	0.92	1.01	1.12	1.29
Asia-Pacific	0.72	0.78	0.86	0.96	1.11

Key Regions and Countries

North America
- US
- Canada
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Key Players Analysis

The cell therapy market is highly competitive, with a mix of established pharmaceutical companies, biotechnology firms, and emerging start-ups driving innovation. The industry is witnessing a surge in strategic collaborations, mergers, and acquisitions as companies aim to strengthen their pipelines and expand global reach.

Research and development investments are accelerating, with a strong focus on next-generation therapies such as CAR-T, TCR-T, and stem cell-based treatments. Many companies are shifting towards allogeneic (off-the-shelf) cell therapies, reducing reliance on patient-derived cells and improving scalability. Automation, AI-driven bioprocessing, and advanced gene-editing techniques are further optimizing production and reducing costs.

Additionally, partnerships between biotech firms and academic institutions are fostering innovation in regenerative medicine and immunotherapy. Regulatory agencies are also playing a crucial role by streamlining approval pathways, enabling faster commercialization of novel therapies. The market landscape is evolving rapidly, with increasing competition and technological advancements shaping its future.

Johnson & Johnson is a global healthcare company engaged in pharmaceuticals, medical devices, and consumer health products. With a strong presence in the cell therapy market, the company focuses on regenerative medicine, immunotherapy, and oncology treatments. In addition, Novartis AG is a Swiss-based multinational pharmaceutical company known for its leadership in oncology, gene therapy, and regenerative medicine. A pioneer in CAR-T cell therapy, Novartis has been instrumental in developing groundbreaking immunotherapies for cancer treatment.

Top Key Players in the Cell Therapy Market

CORESTEMCHEMON Inc.
Dendreon Corp.
Johnson & Johnson
Novartis AG
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company
Gilead Sciences Inc.
JCR Pharmaceuticals Co. Ltd.
Atara Biotherapeutics
Tego Science

Recent Developments

In February 2023, Pierre Fabre and Atara Biotherapeutics, Inc. announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre. Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
In November 2023, Tego Science has successfully demonstrated efficacy in a phase 3 clinical trial of its cell therapy for under-eye wrinkles, fulfilling the conditions for a full license. Rosmir is a self-derived cell therapy indicated for moderate to severe nasojugal grooves.
In June 2021, Dendreon Pharmaceuticals has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.